scispace - formally typeset
I

Isabel Couto

Researcher at Universidade Nova de Lisboa

Publications -  128
Citations -  6264

Isabel Couto is an academic researcher from Universidade Nova de Lisboa. The author has contributed to research in topics: Efflux & Mycobacterium tuberculosis. The author has an hindex of 41, co-authored 122 publications receiving 5577 citations. Previous affiliations of Isabel Couto include University of Lisbon & Rockefeller University.

Papers
More filters
Journal ArticleDOI

Multidrug Efflux Pumps in Staphylococcus aureus: an Update

TL;DR: The current knowledge on MDR efflux pumps and their intricate regulatory network in Staphylococcus aureus, a major pathogen, responsible from mild to life-threatening infections is reviewed and particular emphasis is given to the potential role that S. a Aureus MDRefflux pumps, either chromosomal or plasmid-encoded, have on resistance towards different antimicrobial agents and on the selection of drug - resistant strains.
Journal ArticleDOI

Inferring a Population Structure for Staphylococcus epidermidis from Multilocus Sequence Typing Data

TL;DR: Examination of the sequence changes at MLST loci during clonal diversification showed that recombination gives rise to new alleles approximately twice as frequently as point mutations, suggesting that S. epidermidis has a population with an epidemic structure.
Journal ArticleDOI

Antibiotic stress, genetic response and altered permeability of E. coli.

TL;DR: This study demonstrates that, in addition to the transcriptional regulation of genes coding for membrane proteins, the post-translational regulation of proteins involved in the permeability of Gram-negative bacteria also plays a major role in the physiological adaptation to antibiotic exposure.
Journal ArticleDOI

Contribution of Efflux to the Emergence of Isoniazid and Multidrug Resistance in Mycobacterium tuberculosis

TL;DR: Results support the hypothesis that activity of efflux pumps allows the maintenance of an isoniazid resistant population in a sub-optimally treated patient and should be considered in the development of new therapeutic strategies for preventing the emergence of MDR-TB during treatment.